These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 26568096)

  • 1. Use of biomarkers for assessing radiation injury and efficacy of countermeasures.
    Singh VK; Newman VL; Romaine PL; Hauer-Jensen M; Pollard HB
    Expert Rev Mol Diagn; 2016; 16(1):65-81. PubMed ID: 26568096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A review of radiation countermeasures focusing on injury-specific medicinals and regulatory approval status: part I. Radiation sub-syndromes, animal models and FDA-approved countermeasures.
    Singh VK; Seed TM
    Int J Radiat Biol; 2017 Sep; 93(9):851-869. PubMed ID: 28650707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combining Pharmacological Countermeasures to Attenuate the Acute Radiation Syndrome-A Concise Review.
    Hofer M; Hoferová Z; Depeš D; Falk M
    Molecules; 2017 May; 22(5):. PubMed ID: 28534834
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The efficacy and safety of amifostine for the acute radiation syndrome.
    Singh VK; Seed TM
    Expert Opin Drug Saf; 2019 Nov; 18(11):1077-1090. PubMed ID: 31526195
    [No Abstract]   [Full Text] [Related]  

  • 5. Nonhuman primates as models for the discovery and development of radiation countermeasures.
    Singh VK; Olabisi AO
    Expert Opin Drug Discov; 2017 Jul; 12(7):695-709. PubMed ID: 28441902
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Animal models for acute radiation syndrome drug discovery.
    Singh VK; Newman VL; Berg AN; MacVittie TJ
    Expert Opin Drug Discov; 2015 May; 10(5):497-517. PubMed ID: 25819367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biomarkers for acute radiation syndrome: challenges for developing radiation countermeasures following animal rule.
    Singh VK; Simas M; Pollard H
    Expert Rev Mol Diagn; 2018 Nov; 18(11):921-924. PubMed ID: 30289289
    [No Abstract]   [Full Text] [Related]  

  • 8. Ionizing radiation-induced altered microRNA expression as biomarkers for assessing acute radiation injury.
    Singh VK; Pollard HB
    Expert Rev Mol Diagn; 2017 Oct; 17(10):871-874. PubMed ID: 28792262
    [No Abstract]   [Full Text] [Related]  

  • 9. Development and licensure of medical countermeasures to treat lung damage resulting from a radiological or nuclear incident.
    DiCarlo AL; Jackson IL; Shah JR; Czarniecki CW; Maidment BW; Williams JP
    Radiat Res; 2012 May; 177(5):717-21. PubMed ID: 22468704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A review of radiation countermeasures focusing on injury-specific medicinals and regulatory approval status: part II. Countermeasures for limited indications, internalized radionuclides, emesis, late effects, and agents demonstrating efficacy in large animals with or without FDA IND status.
    Singh VK; Garcia M; Seed TM
    Int J Radiat Biol; 2017 Sep; 93(9):870-884. PubMed ID: 28657406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radioprotective Efficacy of Gamma-Tocotrienol in Nonhuman Primates.
    Singh VK; Kulkarni S; Fatanmi OO; Wise SY; Newman VL; Romaine PL; Hendrickson H; Gulani J; Ghosh SP; Kumar KS; Hauer-Jensen M
    Radiat Res; 2016 Mar; 185(3):285-98. PubMed ID: 26930378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histopathological studies of nonhuman primates exposed to supralethal doses of total- or partial-body radiation: influence of a medical countermeasure, gamma-tocotrienol.
    Singh VK; Wise SY; Fatanmi OO; Petrus SA; Carpenter AD; Lee SH; Hauer-Jensen M; Seed TM
    Sci Rep; 2024 Mar; 14(1):5757. PubMed ID: 38459144
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The characteristic of radioprotective properties of a radioprotectant B-190 at its administration after radiation].
    Vasin MV; Ushakov IB; Kovtun VIu; Komarova SN; Semenova LA; Koroleva LV; Galkin AA; Afanas'ev RV
    Radiats Biol Radioecol; 2008; 48(6):730-3. PubMed ID: 19178051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel biomarkers for acute radiation injury and countermeasures using large and small animal models and multi-omics approach.
    Singh VK; Fatanmi OO; Wise SY; Carpenter AD; Janocha B; Seed TM
    Radiat Prot Dosimetry; 2023 Sep; 199(14):1526-1532. PubMed ID: 37721071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of Drug Products for the Treatment of Acute Radiation Syndrome.
    Libero M
    Disaster Med Public Health Prep; 2024 Jan; 17():e571. PubMed ID: 38163973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Metabolomic Serum Signature from Nonhuman Primates Treated with a Radiation Countermeasure, Gamma-tocotrienol, and Exposed to Ionizing Radiation.
    Pannkuk EL; Laiakis EC; Fornace AJ; Fatanmi OO; Singh VK
    Health Phys; 2018 Jul; 115(1):3-11. PubMed ID: 29787425
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent advances in medical countermeasure development against acute radiation exposure based on the US FDA animal rule.
    MacVittie TJ; Farese AM
    J Radiol Prot; 2021 Nov; 41(4):. PubMed ID: 34433144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. γ-Tocotrienol as a Promising Countermeasure for Acute Radiation Syndrome: Current Status.
    Singh VK; Hauer-Jensen M
    Int J Mol Sci; 2016 May; 17(5):. PubMed ID: 27153057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biologics as countermeasures for acute radiation syndrome: where are we now?
    Singh VK; Romaine PL; Newman VL
    Expert Opin Biol Ther; 2015 Apr; 15(4):465-71. PubMed ID: 25416452
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute radiation syndrome drug discovery using organ-on-chip platforms.
    Singh VK; Seed TM
    Expert Opin Drug Discov; 2022 Aug; 17(8):865-878. PubMed ID: 35838021
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.